TFF Pharmaceuticals Q2 EPS $(0.14) Beats $(0.19) Estimate, Sales $333.35K Beat $70.00K Estimate, Cash Balance of $7.7M Expected to Extend Cash Runway through Q1 of 2024
Portfolio Pulse from Benzinga Newsdesk
TFF Pharmaceuticals reported Q2 earnings per share (EPS) of $(0.14), beating the estimate of $(0.19) by 26.32%. This is a 58.82% increase over the same period last year. The company also reported sales of $333.35K, beating the estimate of $70.00K by 376.22%, a 1.09K% increase from last year. The cash balance of $7.7M is expected to extend the cash runway through Q1 of 2024.
August 15, 2023 | 10:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TFF Pharmaceuticals reported better than expected Q2 earnings and sales, with a significant increase from last year. The company's cash balance is expected to extend the cash runway through Q1 2024.
TFF Pharmaceuticals reported better than expected earnings and sales for Q2, which is likely to have a positive impact on the stock. The significant increase from last year's figures and the extended cash runway also add to the positive outlook for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100